BiVACOR

BiVACOR, Inc. is a clinical-stage medical device company focused on developing the BiVACOR Total Artificial Heart (TAH). This innovative device is designed for long-term therapy in patients with biventricular heart failure, particularly as a bridge to transplant. The TAH is notable for its titanium-based, valveless design that utilizes MAGLEV technology. Founded in 2008 by biomedical engineer Daniel Timms, PhD, BiVACOR is headquartered in Huntington Beach, California, with clinical offices in Houston, Texas, and international offices in Gold Coast, Australia. The company collaborates with institutions like Griffith University and The Texas Heart Institute, which has conducted the first U.S. implant of the TAH. BiVACOR is advancing its product through FDA-approved clinical trials, including an Early Feasibility Study, and has achieved significant milestones such as FDA Breakthrough Device Designation.